Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Faster-acting Insulin Aspart in Type 2 Diabetes
NCT02933853Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin aspart concentration-time curve from 0 to 30 minutes. Started Oct 2016; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02933853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933853.